Get the Stockscreener App
7.85
1.51%
-0.12
After Hours:
7.70
-0.15
-1.91%
Amneal Pharmaceuticals Inc stock is traded at $7.85, with a volume of 829.12K.
It is down -1.51% in the last 24 hours and down -0.25% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$7.97
Open:
$7.89
24h Volume:
829.12K
Relative Volume:
0.71
Market Cap:
$2.43B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-11.54
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
-4.96%
1M Performance:
-0.25%
6M Performance:
+15.27%
1Y Performance:
+46.46%
1-Day Range:
$7.83
$7.96
1-Week Range:
$7.83
$8.275
52-Week Range:
$5.01
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
7.85 | 2.43B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
171.43 | 77.44B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.55 | 43.22B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.53 | 42.94B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.83 | 18.94B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
127.01 | 13.51B | 612.78M | -86.37M | -62.91M | -0.87 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Consensus Target Price from Brokerages - MarketBeat
China Universal Asset Management Co. Ltd. Purchases Shares of 65,698 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Drug Cos. Urge Full Fed. Circ. To Hear Teva Orange Book Row - Law360
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel Sells 80,000 Shares - MarketBeat
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? - MSN
Amneal Pharmaceuticals' SWOT analysis: generic drug maker's stock poised for growth - Investing.com Canada
Wall Street Analysts Predict a 27.12% Upside in Amneal (AMRX): Here's What You Should Know - MSN
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Declines By 6.8% - MarketBeat
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Rising Allergy Prevalence Boosts Growth, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve
SG Americas Securities LLC Has $590,000 Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Says US FDA Accepts New-Drug Application for IPX203 to Treat Parkinson's Disease; Shares Rise - Marketscreener.com
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 - BioSpace
Amneal Sets Key Q4 2024 Earnings DateMark Your Calendar for Major Pharma Update - StockTitan
Amneal Celebrates FDA Approvals For Generic Namzaric And Afinitor Disperz - News & Insights
Is Teva-Amneal Inhaler Case A Double-Edged Sword For The Generics Industry? - News & Insights
Amneal Pharmaceuticals (NASDAQ:AMRX) Trading Up 5.2%Time to Buy? - MarketBeat
Amneal gains FDA approval for dementia and oncology drugs - MSN
Premature Ejaculation Treatment Market to Grow by USD 1.53 Billion (2025-2029), Off-Label Drug Efficacy Boosts Revenue, Report with AI-Powered InsightsTechnavio - The Malaysian Reserve
Amneal Pharmaceuticals Gets FDA Approval for Alzheimer's Treatment and Brain Tumor Drug - MarketWatch
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin - BioSpace
Amneal gains FDA approval for dementia and oncology drugs By Investing.com - Investing.com Australia
Amneal gets FDA approval for generic Byetta, resubmits DHE NDA - MSN
Assenagon Asset Management S.A. Decreases Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Assenagon Asset Management S.A. Trims Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat
Hennessy Advisors Inc. Acquires 106,600 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Is Targeting 70% Of Untapped Biologics In The ‘Golden Era’ Of Biosimilars - Citeline News & Insights
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year? - MSN
FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - MSN
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Driven by Rising Allergy Prevalence; AI Driving Market TransformationTechnavio - The Malaysian Reserve
Amneal expects to meet or top annual guidance - MSN
Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2024 Earnings Guidance - MarketBeat
Amneal Pharmaceuticals Maintains Transparency with SEC Filing - TipRanks
JPMorgan Chase & Co. Grows Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
JPMorgan Chase & Co. Purchases 777,568 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Insider Sell: Gautam Patel Sells 62,590 Shares of Amneal Pharmac - GuruFocus.com
Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Price Target at $10.00 - Defense World
Amneal Pharmaceuticals director Patel sells $501,345 in stock By Investing.com - Investing.com Canada
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel Sells 62,590 Shares - MarketBeat
The 3.1% return this week takes Amneal Pharmaceuticals' (NASDAQ:AMRX) shareholders three-year gains to 74% - Simply Wall St
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Testosterone Replacement Therapy Market to Grow by USD 461 Million (2025-2029), Driven by Awareness Initiatives on Hypogonadism and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Amneal (AMRX) Upgraded to Strong Buy: Here's Why - MSN
Amneal Sues Sandoz to Block Copies of New Parkinson's Drug (1) - Bloomberg Law
Amneal Calls Teva's IP Delisting Panic 'Theatrical Distraction' - Law360
Amneal Pharmaceuticals director Gautam Patel sells $139,454 in stock By Investing.com - Investing.com Nigeria
Insider Selling: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Sells 17,410 Shares of Stock - MarketBeat
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amneal Pharmaceuticals Inc Stock (AMRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Gautam | Director |
Jan 08 '25 |
Sale |
8.01 |
62,590 |
501,346 |
1,968,886 |
| Patel Gautam | Director |
Jan 02 '25 |
Sale |
8.01 |
17,410 |
139,454 |
2,031,476 |
0.57%
3.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):